The application from Lykos — a drug corporation incubated through the Multidisciplinary Affiliation for Psychedelic Experiments, or MAPS — arrived on the FDA underneath a cloud of controversy. Former demo individuals experienced alleged adverse activities were not described — together with inner thoughts of suicidality following the remedy �